Leaderboards/KRAS

KRAS

Last updated May 19, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Julien Dilly
Broad Institute
672 cit.
2
Mary Beth Nierengarten
Unknown
469 cit.
3
Johannes Popow
Boehringer Ingelheim (Austria)
456 cit.
4
Ferdinandos Skoulidis
The University of Texas MD Anderson Cancer Center
435 cit.
5
Jeffrey A. Klomp
University of North Carolina at Chapel Hill
318 cit.
6
Sara R. Savage
Baylor College of Medicine
291 cit.
7
Hartmut Döhner
University Hospital Ulm
252 cit.
8
Jennifer E. Klomp
University of North Carolina at Chapel Hill
240 cit.
9
Mariluz Soula
Rockefeller University
237 cit.
10
Caicun Zhou
Shanghai Pulmonary Hospital
237 cit.

Rising Stars Papers

1
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Cancer Discovery|2024
223 cit.
2
Global cancer statistics 2022
Cancer|2024
468 cit.
3
Targeting cancer with small-molecule pan-KRAS degraders
Science|2024
151 cit.
4
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Nature|2024
144 cit.
5
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Science|2024
105 cit.
6
Pan-cancer proteogenomics expands the landscape of therapeutic targets
Cell|2024
96 cit.
7
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Blood|2024
125 cit.
8
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
Science|2024
79 cit.
9
Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer
Nature|2024
78 cit.
10
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Cancer Cell|2024
78 cit.

Rising Stars Reagents

Coming soon

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Mallika Singh
Revolution Medicines (United States)
855 cit.
2
Piro Lito
Memorial Sloan Kettering Cancer Center
706 cit.
3
Debyani Chakravarty
Memorial Sloan Kettering Cancer Center
379 cit.
4
Eileen M. O’Reilly
Memorial Sloan Kettering Cancer Center
342 cit.
5
Kenneth P. Olive
Columbia University Irving Medical Center
251 cit.
6
Ronald A. DePinho
The University of Texas MD Anderson Cancer Center
248 cit.
7
Humam Kadara
The University of Texas MD Anderson Cancer Center
233 cit.
8
Juan Pedro Martı́nez-Barberá
University College London
223 cit.
9
Shankar Balasubramanian
University of Cambridge
195 cit.
10
Laura D. Wood
Johns Hopkins University
189 cit.

Emerging Leaders Papers

1
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
Nature|2023
483 cit.
2
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Nature|2024
305 cit.
3
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Cancer Discovery|2024
265 cit.
4
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Cancer Discovery|2023
379 cit.
5
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Nature Medicine|2024
228 cit.
6
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Nature|2024
167 cit.
7
An atlas of epithelial cell states and plasticity in lung adenocarcinoma
Nature|2024
155 cit.
8
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Science|2023
223 cit.
9
Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer
Cancer Cell|2023
223 cit.
10
G-quadruplex DNA structure is a positive regulator of <i>MYC</i> transcription
Proceedings of the National Academy of Sciences|2024
130 cit.

Emerging Leaders Reagents

Coming soon

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Pier Paolo Pandolfi
Beth Israel Deaconess Medical Center
30.1k cit.
2
David A. Tuveson
Cancer Research Institute
22k cit.
3
Raghu Kalluri
The University of Texas MD Anderson Cancer Center
16.2k cit.
4
William C. Hahn
Dana-Farber Cancer Institute
12.5k cit.
5
Solange Peters
University Hospital of Lausanne
9.8k cit.
6
David Chang
Universitair Ziekenhuis Leuven
9.4k cit.
7
Aristotelis Tsirigos
Telio (Norway)
8.5k cit.
8
J. Russell Lipford
Amgen (United States)
6.7k cit.
9
Feng Zhang
McGovern Institute for Brain Research
6.1k cit.
10
Ronald A. DePinho
Harvard University
6.1k cit.

All-Time Leaders Papers

1
Comprehensive molecular characterization of human colon and rectal cancer
Nature|2012
8.6k cit.
2
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Cell|2011
7.7k cit.
3
Integrated genomic characterization of endometrial carcinoma
Nature|2013
5.8k cit.
4
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Nature|2009
4.2k cit.
5
Genomic analyses identify molecular subtypes of pancreatic cancer
Nature|2016
3.7k cit.
6
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Journal of Clinical Oncology|2008
3.1k cit.
7
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
Nature|2015
2.8k cit.
8
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
Nature Medicine|2018
2.8k cit.
9
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
Cancer Cell|2005
2.6k cit.
10
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Nature|2017
2.6k cit.

All-Time Leaders Reagents

Coming soon

Indexing KRAS Reagents

Citation data for reagents in this field is currently compiling.